trial

The Effects of ∆-9-THC and Naloxone in Humans

NCTId NCT01591629
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Early Phase 1 · Completed
Enrollment 6 (actual)
Sponsored by Yale University
Primary completion 2012-06-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Early Phase 1
Status
Completed
Enrollment
6 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2011-11-04
Primary completion
2012-06-01
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
NaloxoneDelta-9-THC

Sponsors

Yale UniversityLead Sponsor

Sites

1 total
West Haven, United States

Facts & assertions

4 sourced
Enrollment
6
Phase
EARLY_PHASE1
Primary Completion Date
2012-06-01
Status
COMPLETED
relationships
The graph out of here
drug
Naloxone
drug
Delta-9-THC
drug
lead_sponsor
Yale University
company
indication
Psychotic Disorders
indication
Healthy
indication
Marijuana Abuse
indication